Početna › Nemikrocelularni karcinom pluća › Minnesota
Kliničke studije za Nemikrocelularni karcinom pluća u državi Minnesota
69 studija za Nemikrocelularni karcinom pluća traži sudionike na lokacijama u državi Minnesota.
Gradovi u državi Minnesota
- Rochester37 studija
- Minneapolis26 studija
- Saint Paul18 studija
- Duluth13 studija
- Brooklyn Park10 studija
- Bloomington10 studija
- Plymouth8 studija
- Saint Cloud3 studija
Službeni tekst studije (engleski)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Sanford Joe Lueken Cancer Center, Bemidji
- Minnesota Oncology - Burnsville, Burnsville
- Mercy Hospital, Coon Rapids
- i još 16
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT04267848A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
- Sanford Joe Lueken Cancer Center, Bemidji
- Essentia Health Saint Joseph's Medical Center, Brainerd
- Essentia Health - Deer River Clinic, Deer River
- i još 6
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT07293247Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #68, Rochester
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 1. lis 2026. · NCT05176483Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer
- Mayo Clinic in Rochester, Rochester
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 1. lis 2026. · NCT06918132A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Health Partners Frauenshuh Cancer Center, Saint Louis Park
- Health Partners Cancer Center at Regions Hospital, Saint Paul
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 1. lis 2026. · NCT06172478A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- HealthPartners Cancer Research Center /ID# 277339, Saint Louis Park
U tijeku regrutacijaFaza 2/3
Od 18 godina i više · Oba spola · Ažurirano 1. lis 2026. · NCT07155187Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Sanford Joe Lueken Cancer Center, Bemidji
- Essentia Health Saint Joseph's Medical Center, Brainerd
- Mercy Hospital, Coon Rapids
- i još 12
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 1. lis 2026. · NCT06498635A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
- Research Site, Rochester
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 1. lis 2026. · NCT06996782A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Minnesota Oncology Hematology, Maple Grove
- Allina Health Cancer Institute - Abbott Northwestern Hospital, Minneapolis
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT07361497Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- St. Luke'S /ID# 273344, Duluth
- Mayo Clinic-Rochester /ID# 274512, Rochester
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 29. ruj 2026. · NCT06772623A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Minnesota Oncology Hematology, PA, Burnsville
- Allina Health Cancer Institute - Mercy Hospital, Coon Rapids
- Minnesota Oncology Hematology, PA, Coon Rapids
- i još 7
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT07144280A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Allina Health Cancer Institute - Abbott Northwestern Hospital ( Site 0027), Minneapolis
- Mayo Clinic - Rochester ( Site 0073), Rochester
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT06312137Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Minnesota Oncology Hematology, P.A., Burnsville
- Minnesota Oncology Hematology, P.A., Chaska
- Allina Health Cancer Institute - Mercy Hospital, Coon Rapids
- i još 7
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT07222566Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Mayo Clinic Rochester, Rochester
U tijeku regrutacijaOpažajna studija
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT04981119This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Minnesota Oncology Hematology, PA, Burnsville
- Minnesota Oncology Hematology PA, Coon Rapids
- M Health Fairview Cancer Clinic-Edina, Edina
- i još 10
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT06758401A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- University Of Minnesota, Minneapolis
- Mayo Clinic Rochester, Rochester
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT06667076A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Mayo Clinic, Rochester
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT07154290Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- Allina Health Cancer Institute - Abbott Northwestern Hospital ( Site 0115), Minneapolis
- Mayo Clinic - Rochester ( Site 0148), Rochester
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT06170788Pan-tumor MRD Study
- Mayo Clinic, Rochester
U tijeku regrutacijaOpažajna studija
Od 18 godina i više · Oba spola · Ažurirano 24. ruj 2026. · NCT06605404Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- Minnesota Oncology - Burnsville, Burnsville
- Cambridge Medical Center, Cambridge
- Minnesota Oncology Hematology PA-Chaska, Chaska
- i još 23
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 24. ruj 2026. · NCT03191149An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer
- Mayo Clinic, Rochester
U tijeku regrutacijaFaza 2
Od 18 do 80 godina · Oba spola · Ažurirano 24. ruj 2026. · NCT06693336A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Research Site, Duluth
- Research Site, Rochester
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 18. ruj 2026. · NCT06692738Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Clinical Study Sites, Duluth
- Clinical Study Site, Minneapolis
- Clinical Study Site, Saint Paul
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 18. ruj 2026. · NCT06767514Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Minnesota Oncology and Hematology PA, Minneapolis
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 18. ruj 2026. · NCT05267626Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Masonic Cancer Center University of Minnesota, Minneapolis
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 16. ruj 2026. · NCT05786924Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- USOR - Minnesota Oncology - Burnsville, Burnsville
- Local Institution - 007-589A, Edina
U tijeku regrutacijaFaza 2/3
Od 18 godina i više · Oba spola · Ažurirano 16. ruj 2026. · NCT04613596Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
- Mayo Clinic, Rochester
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 15. ruj 2026. · NCT06899126ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Mayo Clinic (Rochester), Rochester
U tijeku regrutacijaOpažajna studija
Od 18 godina i više · Oba spola · Ažurirano 14. ruj 2026. · NCT05059444A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
- Mayo Clinic, Rochester
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 10. ruj 2026. · NCT04302025A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Allina Health Cancer Institute - Abbott Northwestern Hospital, Minneapolis
- HealthPartners Cancer Research Center, Saint Paul
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 8. ruj 2026. · NCT06119581A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
- Mayo Rochester, Rochester
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 4. ruj 2026. · NCT07361562Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
- Research Site, Rochester
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 4. ruj 2026. · NCT07291037Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
- Allina Health Cancer Institute - Abbott Northwestern Hospital ( Site 0146), Minneapolis
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 3. ruj 2026. · NCT06422143FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
- University of Minnesota Masonic Cancer Center, Minneapolis
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 2. ruj 2026. · NCT07216105A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
- Mayo Clinic, Rochester
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 2. ruj 2026. · NCT07027514Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
- Mayo Clinic, Rochester
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 2. ruj 2026. · NCT05245500A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
- Mayo Clinic - Rochester, Rochester
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 2. ruj 2026. · NCT04913285Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Research Site, Saint Paul
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 26. kol 2026. · NCT06350097A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
- Mayo Clinic-Rochester, Rochester
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 26. kol 2026. · NCT06892548A Tool for Improving the Shared Decision-making Process in Patients With Non-small Cell Lung Cancer
- Mayo Clinic in Rochester, Rochester
U tijeku regrutacijaZdravi dobrovoljci dobrodošli
Od 18 godina i više · Oba spola · Ažurirano 20. kol 2026. · NCT06122064Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.